Therefore, this study aims to evaluate the cost-effectiveness of iruplinalkib versus crizotinib in treatment-naïve ALK + NSCLC patients from the perspective of the Chinese healthcare system, based on the INSPIRE clinical trial. Here, ALK is linked to non-small cell lung carcinoma.